Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality

Angelo Karaboyas (1) , Friedrich K. Port (1) , Ziad A. Massy (2, 3, 4) , Francesco Locatelli (5) , Aleix Cases (6) , Kosaku Nitta (7) , Sophie Liabeuf (8, 9) , Kitty J. Jager (10) , Bruce M. Robinson (1, 11)

1 Arbor Research Collaborative for Health
2 UVSQ Santé - Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil
3 Service Néphrologie/Dialyse [AP-HP Ambroise-Paré]
4 CESP - Centre de recherche en épidémiologie et santé des populations
5 Alessandro Manzoni Hospital
6 UB - Universitat de Barcelona
7 TWMU - Tokyo Women's Medical University
8 CHU Amiens-Picardie
9 MP3CV - Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517
10 UvA - University of Amsterdam [Amsterdam]
11 University of Michigan [Ann Arbor]

No abstract available

Domaines: Sciences du Vivant [q-bio]

Angelo Karaboyas, Friedrich K. Port, Ziad A. Massy, Francesco Locatelli, Aleix Cases, et al.. Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality. Kidney International Reports, 2020, 6 (1), pp.214-218. ⟨10.1016/j.ekir.2020.10.003⟩. ⟨hal-03578662⟩